A memorial tribute to Henry L. Jaffe (1896–1979), widely regarded as the most distinguished bone pathologist of modern times. The piece catalogs his career at The Hospital for Joint Diseases and the nine skeletal disorders he described or reclassified. It documents the analytic framework he established — correlating history, imaging, and histology — that still governs bone lesion evaluation today.
Every time you present a bone lesion — leading with plain radiographs, correlating with the clinical history, then confirming with histology. You are using Jaffe's method. He formalized this three-part approach decades before it became standard of care.
For boards and clinical practice, the nine entities Jaffe named are the backbone of the bone tumor differential. When an OITE stem asks which lesion was "originally described" or asks you to match a lesion to its classic histologic and radiographic features, you are being tested on Jaffe's work directly.
The entity list is worth memorizing in chronological order: osteoblastoma (1932), osteoid osteoma (1935), giant cell tumor and eosinophilic granuloma (1940), PVNS (1941), chondroblastoma and non-ossifying fibroma (1942), chondromyxoid fibroma (1948), and aneurysmal bone cyst (1952).
This tribute is a REFERENCE-tier article. Not a study to analyze, but a historical anchor for understanding why these classification names exist and where the diagnostic framework you use every day originated.
A memorial tribute to Henry L. Jaffe (1896–1979), widely regarded as the most distinguished bone pathologist of modern times. The piece catalogs his career at The Hospital for Joint Diseases and the nine skeletal disorders he described or reclassified. It documents the analytic framework he established — correlating history, imaging, and histology — that still governs bone lesion evaluation today.
Every time you present a bone lesion — leading with plain radiographs, correlating with the clinical history, then confirming with histology. You are using Jaffe's method. He formalized this three-part approach decades before it became standard of care.
For boards and clinical practice, the nine entities Jaffe named are the backbone of the bone tumor differential. When an OITE stem asks which lesion was "originally described" or asks you to match a lesion to its classic histologic and radiographic features, you are being tested on Jaffe's work directly.
The entity list is worth memorizing in chronological order: osteoblastoma (1932), osteoid osteoma (1935), giant cell tumor and eosinophilic granuloma (1940), PVNS (1941), chondroblastoma and non-ossifying fibroma (1942), chondromyxoid fibroma (1948), and aneurysmal bone cyst (1952).
This tribute is a REFERENCE-tier article. Not a study to analyze, but a historical anchor for understanding why these classification names exist and where the diagnostic framework you use every day originated.